Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

ClinicalTrials.gov ID: NCT07000123

Public ClinicalTrials.gov record NCT07000123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Study identification

NCT ID
NCT07000123
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
3,103 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 28, 2025 (Actual)
Primary completion
Jan 11, 2027 (Estimated)
Completion
Jan 11, 2027 (Estimated)
Last update posted
Aug 11, 2026

2025 – 2027

United States locations

U.S. sites
101
U.S. states
26
U.S. cities
95
Facility City State ZIP Site status
Research Site Huntsville Alabama 35801 —
Research Site Irondale Alabama 35210 —
Research Site Mobile Alabama 36608 —
Research Site Gilbert Arizona 85296 —
Research Site Phoenix Arizona 85014 —
Research Site Sun City West Arizona 85375 —
Research Site Garden Grove California 92844 —
Research Site Gardena California 90247 —
Research Site Lancaster California 93534 —
Research Site Lincoln California 95648 —
Research Site San Diego California 92103 —
Research Site San Diego California 92111 —
Research Site Torrance California 90502 —
Research Site West Hills California 91307 —
Research Site Hamden Connecticut 06517 —
Research Site Boca Raton Florida 33434 —
Research Site Hallandale Florida 33009 —
Research Site Hialeah Florida 33012 —
Research Site Inverness Florida 34452 —
Research Site Jacksonville Florida 32216 —
Research Site Miami Florida 33176 —
Research Site New Port Richey Florida 34653 —
Research Site Orlando Florida 32807 —
Research Site Pembroke Pines Florida 33029 —
Research Site Seminole Florida 33777 —
Research Site Tampa Florida 33625 —
Research Site Atlanta Georgia 30328 —
Research Site Atlanta Georgia 30342 —
Research Site Decatur Georgia 30030 —
Research Site Peachtree Corners Georgia 30092 —
Research Site Chicago Illinois 60607 —
Research Site Winfield Illinois 60190 —
Research Site Evansville Indiana 47714 —
Research Site Evansville Indiana 47715 —
Research Site Indianapolis Indiana 46260 —
Research Site Ames Iowa 50010 —
Research Site El Dorado Kansas 67042 —
Research Site Wichita Kansas 67218 —
Research Site Owensboro Kentucky 42301 —
Research Site Hammond Louisiana 70403 —
Research Site Kenner Louisiana 70065 —
Research Site Lafayette Louisiana 70508 —
Research Site Lake Charles Louisiana 70601 —
Research Site Shreveport Louisiana 71105 —
Research Site Zachary Louisiana 70791 —
Research Site Annapolis Maryland 21401 —
Research Site Baltimore Maryland 21229 —
Research Site Beltsville Maryland 20705 —
Research Site Potomac Maryland 20854 —
Research Site Chesterfield Missouri 63005 —
Research Site Jefferson City Missouri 65109 —
Research Site Kansas City Missouri 64131 —
Research Site Missoula Montana 59808 —
Research Site Buffalo New York 14217 —
Research Site Rochester New York 14609 —
Research Site The Bronx New York 10451 —
Research Site Durham North Carolina 27701 —
Research Site Greensboro North Carolina 27408 —
Research Site Hickory North Carolina 28601 —
Research Site Morganton North Carolina 28655 —
Research Site New Bern North Carolina 28562 —
Research Site Raleigh North Carolina 27609 —
Research Site Rocky Mount North Carolina 27804 —
Research Site Salisbury North Carolina 28144 —
Research Site Statesville North Carolina 28625 —
Research Site Wilmington North Carolina 28401 —
Research Site Fargo North Dakota 58104 —
Research Site Blue Ash Ohio 45242 —
Research Site Columbus Ohio 43213 —
Research Site Columbus Ohio 43215 —
Research Site Lima Ohio 45805 —
Research Site Camp Hill Pennsylvania 17011 —
Research Site Horsham Pennsylvania 19044 —
Research Site Philadelphia Pennsylvania 19114 —
Research Site West Chester Pennsylvania 19380 —
Research Site Anderson South Carolina 29621 —
Research Site Fort Mill South Carolina 29707 —
Research Site Mauldin South Carolina 29662 —
Research Site Mt. Pleasant South Carolina 29464 —
Research Site North Charleston South Carolina 29405 —
Research Site Rapid City South Dakota 57701 —
Research Site Bristol Tennessee 37620 —
Research Site Knoxville Tennessee 37849 —
Research Site Knoxville Tennessee 37912 —
Research Site Knoxville Tennessee 37938 —
Research Site Beaumont Texas 77706 —
Research Site El Paso Texas 79902 —
Research Site Houston Texas 77043 —
Research Site Humble Texas 77338 —
Research Site Irving Texas 75061 —
Research Site Katy Texas 77450 —
Research Site Mesquite Texas 75149 —
Research Site Paris Texas 75462 —
Research Site San Antonio Texas 78229 —
Research Site San Marcos Texas 78666 —
Research Site Sugar Land Texas 77478 —
Research Site Charlottesville Virginia 22911 —
Research Site Hampton Virginia 23666 —
Research Site Norfolk Virginia 23504 —
Research Site Suffolk Virginia 23435 —
Research Site Redmond Washington 98052 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 303 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07000123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07000123 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →